explore -WSS

explore

author：explore 2025-09-10 01:00:51 - browse：2

By some measures, private equity investment lagged in 2023, a year marked by growing distress and high-profile downfalls among private equity-backed health care companies.

Even so, three sectors still managed to see strong deal flow and prices: med spa, cardiology, and clinical trial sites, according to a new PitchBook report analyzing private equity investments in health care services in 2023. Each of the three niches continue to generate buzz among investors, even as other areas fizzle.

It’s not that those three industries are perfect fits for private equity, it’s that the more obvious areas like autism therapists and physician practices are struggling with high interest rates and regulatory scrutiny, said Rebecca Springer, PitchBook’s lead health care analyst.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Peter Hotez and the public health issue of online harassment
Next article： What American doctors can learn from their Israeli counterparts

WSS

How to fix cancer clinical trials' diversity problem

Diversifying clinical trials isn't enough to close racial gaps: study

Why Sanofi got shellacked over its spinoff

Weighted lottery helped low

How to protect patients from sexual assault

The FDA weighs the risks of candy

leisure time

explore

Wikipedia

Medical records are filled with copy

Physician subsidies by hospitals soar in wake of No Surprises Act

As demand for Covid shots wanes, Moderna seeks its next success

Seth Rogen and Lauren Miller Rogen on Alzheimer's caregiving

What does generative AI mean for health care? We asked experts

Readout Newsletter: New research from Sanofi, Regeneron, etc.

Peter Hotez and the public health issue of online harassment

Illumina names Agilent executive as new CEO

How to save PrEP access — and even expand it

FDA approves Eli Lilly ulcerative colitis treatment Omvoh

explore

Cassava reveals details — and problems — with Alzheimer's study

AstraZeneca chief proposes a novel edit to the drug pricing bill

Physician subsidies by hospitals soar in wake of No Surprises Act

Snackable artificial intelligence, expert AI, and the pharma industry

CDC recommends rationing of RSV shot due to shortages

Readout Newsletter: The latest from Bristol, Sarepta, and Novartis

knowledge

focus

hotspot

Wikipedia